Trial Profile
A double-blinded extension study to provide adjuvant treatment with single agent Herceptin or TX05 and assess continued safety and immunogenicity in subjects with HER2-positive early breast cancer following neoadjuvant treatment and surgical resection in Protocol TX05-03
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Oct 2022
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
- Sponsors Tanvex BioPharma
- 07 Jun 2022 Results assessing and characterizing assess and characterize the safety, immunogenicity, and efficacy of TX05 and TRA as single agents presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 25 Apr 2022 Status changed from active, no longer recruiting to completed.
- 25 Mar 2022 This trial has been completed in Hungary, according to European Clinical Trials Database record.